Hangzhou Bio-Sincerity Pharma-TechLtd Balance Sheet Health
Financial Health criteria checks 4/6
Hangzhou Bio-Sincerity Pharma-TechLtd has a total shareholder equity of CN¥2.7B and total debt of CN¥634.4M, which brings its debt-to-equity ratio to 23.1%. Its total assets and total liabilities are CN¥3.8B and CN¥1.1B respectively. Hangzhou Bio-Sincerity Pharma-TechLtd's EBIT is CN¥319.5M making its interest coverage ratio -12.3. It has cash and short-term investments of CN¥790.6M.
Key information
23.1%
Debt to equity ratio
CN¥634.42m
Debt
| Interest coverage ratio | -12.3x |
| Cash | CN¥790.56m |
| Equity | CN¥2.74b |
| Total liabilities | CN¥1.09b |
| Total assets | CN¥3.83b |
Recent financial health updates
No updates
Financial Position Analysis
Short Term Liabilities: 301096's short term assets (CN¥1.7B) exceed its short term liabilities (CN¥963.4M).
Long Term Liabilities: 301096's short term assets (CN¥1.7B) exceed its long term liabilities (CN¥129.9M).
Debt to Equity History and Analysis
Debt Level: 301096 has more cash than its total debt.
Reducing Debt: 301096's debt to equity ratio has increased from 7.2% to 23.1% over the past 5 years.
Debt Coverage: 301096's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: 301096 earns more interest than it pays, so coverage of interest payments is not a concern.